

ACCESS DB # 177478
PLEASE PRINT CLEARLY

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARK BERCH Examiner #: 59193 Date: 1/24/06
Art Unit: 1624 Phone Number: 2- 0663 Serial Number: 1023576
Location (Bldg/Room#): 5 CO1 (Mailbox #): 5C18 Results Format Preferred (circle): PAPER DISK

Also 10791979

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Date: _____


Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Compound must have this fragment:



| | | |
|------------------------------------|--|---|
| STAFF USE ONLY | Type of Search | Vendors and cost where applicable |
| Searcher: _____ | <input type="checkbox"/> NA Sequence (#) | <input type="checkbox"/> STN <input type="checkbox"/> Dialog |
| Searcher Phone #: _____ | <input type="checkbox"/> AA Sequence (#) | <input type="checkbox"/> Questel/Orbit <input type="checkbox"/> Lexis/Nexis |
| Searcher Location: _____ | <input type="checkbox"/> Structure (#) | <input type="checkbox"/> Westlaw <input type="checkbox"/> WWW/Internet |
| Date Searcher Picked Up: _____ | <input type="checkbox"/> Bibliographic | <input type="checkbox"/> In-house sequence systems |
| Date Completed: _____ | <input type="checkbox"/> Litigation | <input type="checkbox"/> Commercial <input type="checkbox"/> Oligomer <input type="checkbox"/> Score/Length <input type="checkbox"/> Interference <input type="checkbox"/> SPDI <input type="checkbox"/> Encode/Transl <input type="checkbox"/> Other (specify) _____ |
| Searcher Prep & Review Time: _____ | <input type="checkbox"/> Fulltext | |
| Online Time: _____ | <input type="checkbox"/> Other | |

=> d his full

(FILE 'HOME' ENTERED AT 11:31:54 ON 27 JAN 2006)

FILE 'LREGISTRY' ENTERED AT 11:34:55 ON 27 JAN 2006
L1 STRUCTURE

FILE 'REGISTRY' ENTERED AT 11:50:12 ON 27 JAN 2006
L2 0 SEA SSS SAM L1
L3 9 SEA SSS FUL L1

FILE 'HCAPLUS' ENTERED AT 11:51:17 ON 27 JAN 2006
L4 2 SEA ABB=ON PLU=ON L3

FILE 'BEILSTEIN' ENTERED AT 11:51:33 ON 27 JAN 2006
L5 0 SEA SSS SAM L1
L6 0 SEA SSS FUL L1

FILE 'MARPAT' ENTERED AT 11:52:08 ON 27 JAN 2006
L7 0 SEA SSS SAM L1
L8 2 SEA SSS FUL L1
L9 0 SEA ABB=ON PLU=ON L8 NOT L4

FILE 'CAOLD' ENTERED AT 11:52:45 ON 27 JAN 2006
S L1

FILE 'REGISTRY' ENTERED AT 11:52:50 ON 27 JAN 2006
L10 0 SEA SSS SAM L1

FILE 'CAOLD' ENTERED AT 11:52:52 ON 27 JAN 2006
L11 0 SEA ABB=ON PLU=ON L10
L12 0 SEA ABB=ON PLU=ON L3

FILE HOME

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JAN 2006 HIGHEST RN 872674-04-9
DICTIONARY FILE UPDATES: 25 JAN 2006 HIGHEST RN 872674-04-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *

* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Jan 2006 VOL 144 ISS 6
FILE LAST UPDATED: 26 Jan 2006 (20060126/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE BEILSTEIN

FILE LAST UPDATED ON JANUARY 17, 2006

FILE COVERS 1771 TO 2005.

FILE CONTAINS 9,428,406 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.
Reaction data for BEILSTEIN compounds may be displayed
immediately with the display codes PRE (preparations) and REA
(reactions). A substance answer set retrieved after the search
for a chemical name, a compounds with available reaction
information by combining with PRE/FA, REA/FA or more generally
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
between a BEILSTEIN compound and belonging reactions. For more
detailed reaction searches BRNs can be searched as reaction
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *

* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *

* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *

* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.
* FOR PRICE INFORMATION SEE HELP COST

*

NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE
SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,
ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A
COMPOUND AT A GLANCE.

FILE MARPAT

FILE CONTENT: 1969-PRESENT (VOL 144 ISS 4 (20060120/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1969-1987

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6958359 25 OCT 2005
DE 1020040544 27 OCT 2005
EP 1589024 26 OCT 2005
JP 2005320486 27 OCT 2005
WO 2005110983 24 NOV 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

FILE CAOLD

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> file hcaplus

FILE 'HCAPLUS' ENTERED AT 11:53:21 ON 27 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing


of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jan 2006 VOL 144 ISS 6
FILE LAST UPDATED: 26 Jan 2006 (20060126/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que stat 14
L1 STR



REP G1=(0-20) C

VAR G2=H/34

VPA 32-25/30/29/28 U

NODE ATTRIBUTES:

NSPEC IS C AT 34

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 26 18 3 12

NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE

L3 9 SEA FILE=REGISTRY SSS FUL L1

L4 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

=> d 14 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:759822 HCAPLUS

DOCUMENT NUMBER: 141:260450

TITLE: Processes for preparation of substituted azetidinone compounds, formulations containing them and uses thereof

INVENTOR(S): Burnett, Duane A.; Clader, John W.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 30 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| US 2004180861 | A1 | 20040916 | US 2004-792346 | 20040303 |
| CA 2517572 | AA | 20040923 | CA 2004-2517572 | 20040303 |
| WO 2004081003 | A1 | 20040923 | WO 2004-US6428 | 20040303 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1601669 | A1 | 20051207 | EP 2004-716913 | 20040303 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRIORITY APPLN. INFO.: | | | US 2003-452725P | P 20030307 |
| | | | WO 2004-US6428 | W 20040303 |

OTHER SOURCE(S): MARPAT 141:260450
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides substituted azetidinone compds. I [X1 = Xm; X2 = Cq; X3 = Yn; X4 = Cr; X5 = Zp; X, Y, Z = CH₂, CH-alkyl, C(Alkyl)₂; Q1, Q2 = H, (C0-30-alkylene)-G, OR₆, O₂CR₆, OCO₂R₉, O₂CNR₆R₇, L-M; Q3 = 1 - 5 substituents, selected from alkyl, alkenyl, alkynyl, (C0-30-alkylene)-G, (C0-10-alkylene)-OR₆, (C0-10-alkylene)-C(:O)R₆, (C0-10-alkylene)-CO₂R₆, (C0-10-alkylene)O₂CR₆, CH:CHCOR₆, CH:CHCO₂R₆, C.tplbond.CCO₂R₆, C.tplbond.CC(:O)R₆, etc.; Q4 = ; Q5 = ; G = sugar, oligo sugar, amino sugar, amino acid, oligopeptide (2 - 9 residues), trialkylammoniumalkyl, SO₃H; L = OC(:O)C₆H₄C(:O)-4, OCO(:O)(CH₂)_{x1}C(:O), (CH₂)_{x2}C(:O), O(CH₂)_{x3}C(:O), OSiMe₂(CH₂)_{x4}C(:O), OSiMe₂(CH₂)_{x5}O₂C(:O), etc.; M = statin linked through O (atorvastatin, simvastatin); R₂, R₃ = H, alkyl, aryl; R₆, R₇, R₈ = H, alkyl, aryl, aralkyl; R₉ = alkyl, aryl, aralkyl; R₁₀ = H, alkyl; q = 0, 1; r = 0, 1; m, n, p = 0 - 4 (with the proviso that, at least one of q and r = 1, and the sum of m + n + p + q + r = 1 - 6; with the proviso that when p = 0, r = 1 and the sum of m + q + n = 1 - 5); x₁ - x₁₁ = 1 - 10; with the proviso that at least one of Q1 - Q5 = L-M, mono-, di-, tri-, tetrasugar, sugar acid, amino sugar, amino acid, etc.], formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject. Thus, azetidinone conjugate II can be prepared from ezetimibe acetate (III) via acylation with glutaric anhydride and esterification with simvastatin (IV).

IT 756821-84-8P 756821-86-0P 756821-90-6P

756821-92-8P 756821-93-9P 756821-94-0P

756821-95-1P 756821-96-2P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted azetidinone compds. useful for treating vascular conditions)

RN 756821-84-8 HCPLUS

CN Pentanedioic acid, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl (2S,4S,4aR,5S,6S)-2,3,4,4a,5,6-hexahydro-6-methyl-4-[(2S)-2-methyl-1-oxobutoxy]-5-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756821-86-0 HCPLUS

CN Pentanedioic acid, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl (2R,4R)-2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—F

RN 756821-90-6 HCAPLUS

CN Butanoic acid, 4-[4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenoxy]-, (2R,4R)-2-[2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


$$\begin{array}{c} \parallel \\ \text{O} \end{array}$$

RN 756821-92-8 HCAPLUS


CN Pentanedioic acid, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl (2S,4R)-2-[2-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-2,6-dimethyl-1-naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 756821-93-9 HCAPLUS

CN Pentanedioic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl 2-[2-[(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—F

RN 756821-94-0 HCAPLUS
 CN Butanoic acid, 4-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenoxy]-, 2-[2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 756821-95-1 HCAPLUS

CN Pentanedioic acid, 4-[3-[3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl 2-[2-[1,2,6,7,8,8a-hexahydro-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)



RN 756821-96-2 HCPLUS

CN Pentanedioic acid, 4-[3-[3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl 2,3,4,4a,5,6-hexahydro-6-methyl-4-(2-methyl-1-oxobutoxy)-5-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:759821 HCPLUS

DOCUMENT NUMBER: 141:254573

TITLE: Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

INVENTOR(S): Burnett, Duane A.; Clader, John W.

PATENT ASSIGNEE(S): Schering Corporation, USA


SOURCE: U.S. Pat. Appl. Publ., 35 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| US 2004180860 | A1 | 20040916 | US 2004-791979 | 20040303 |
| CA 2517573 | AA | 20040923 | CA 2004-2517573 | 20040303 |
| WO 2004081004 | A1 | 20040923 | WO 2004-US6555 | 20040303 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1606287 | A1 | 20051221 | EP 2004-716968 | 20040303 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRIORITY APPLN. INFO.: | | | US 2003-452722P | P 20030307 |
| | | | WO 2004-US6555 | W 20040303 |

OTHER SOURCE(S): MARPAT 141:254573
 GI



AB This invention provides for pharmaceutical formulations and processes for preparing substituted azetidinone compds. of the general form G-L-M [G = azetidinone moiety, such as I; L = linking group, such as -OCO(CH₂)₂NH-; M = pharmaceutically active moiety, such as simvastatin], which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination, lowering plasma levels of sterols, stanols and/or cholesterol and regulating levels of amyloid β peptides or treating Alzheimer's disease. A hypothetical in vivo evaluation of hypercholesterolemic activity using Golden Syrian hamster was presented.


IT 756879-00-2DP, analogs
 RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (azetidinones for use in pharmaceutical compns. for treatment of vascular diseases)

RN 756879-00-2 HCPLUS

CN β -Alanine, N-[(3R,4S,4aR,5S,7R)-5-(2,2-dimethyl-1-oxobutoxy)-3,4,4a,5,6,7-hexahydro-3,7-dimethyl-4-[2-(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl]carbonyl]-, 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxo-2-azetidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

/ Et